These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34516560)

  • 1. Rift Valley fever virus 78kDa envelope protein attenuates virus replication in macrophage-derived cell lines and viral virulence in mice.
    Terasaki K; Kalveram B; Johnson KN; Juelich T; Smith JK; Zhang L; Freiberg AN; Makino S
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009785. PubMed ID: 34516560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
    Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
    J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.
    Wichgers Schreur PJ; Oreshkova N; Moormann RJ; Kortekaas J
    J Virol; 2014 Sep; 88(18):10883-93. PubMed ID: 25008937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.
    Bamia A; Marcato V; Boissière M; Mansuroglu Z; Tamietti C; Romani M; Simon D; Tian G; Niedergang F; Panthier JJ; Flamand M; Souès S; Bonnefoy E
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33087469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Insight into the Host Transcription Inhibition Function of Rift Valley Fever Virus NSs and Its Importance in Virulence.
    Terasaki K; Ramirez SI; Makino S
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005047. PubMed ID: 27711108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Phosphatase-1 regulates Rift Valley fever virus replication.
    Baer A; Shafagati N; Benedict A; Ammosova T; Ivanov A; Hakami RM; Terasaki K; Makino S; Nekhai S; Kehn-Hall K
    Antiviral Res; 2016 Mar; 127():79-89. PubMed ID: 26801627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    Ly HJ; Lokugamage N; Nishiyama S; Ikegami T
    PLoS One; 2017; 12(9):e0185194. PubMed ID: 28926632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
    Terasaki K; Tercero BR; Makino S
    Virus Res; 2016 May; 216():55-65. PubMed ID: 26022573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limiting viral replication in hepatocytes alters Rift Valley fever virus disease manifestations.
    Xu L; Paine AC; Barbeau DJ; Alencastro F; Duncan AW; McElroy AK
    J Virol; 2023 Sep; 97(9):e0085323. PubMed ID: 37695055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    McMillen CM; Megli C; Radisic R; Skvarca LB; Hoehl RM; Boyles DA; McGaughey JJ; Bird BH; McElroy AK; Hartman AL
    J Virol; 2024 Aug; 98(8):e0098324. PubMed ID: 39016561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.
    Nishiyama S; Slack OA; Lokugamage N; Hill TE; Juelich TL; Zhang L; Smith JK; Perez D; Gong B; Freiberg AN; Ikegami T
    Virulence; 2016 Nov; 7(8):871-881. PubMed ID: 27248570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of Rift Valley fever virus and the emergence of reassortants.
    Gaudreault NN; Indran SV; Balaraman V; Wilson WC; Richt JA
    Virus Genes; 2019 Feb; 55(1):1-11. PubMed ID: 30426314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.
    Gowen BB; Bailey KW; Scharton D; Vest Z; Westover JB; Skirpstunas R; Ikegami T
    Antiviral Res; 2013 May; 98(2):135-43. PubMed ID: 23523764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.
    Scharton D; Bailey KW; Vest Z; Westover JB; Kumaki Y; Van Wettere A; Furuta Y; Gowen BB
    Antiviral Res; 2014 Apr; 104():84-92. PubMed ID: 24486952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice.
    Terasaki K; Juelich TL; Smith JK; Kalveram B; Perez DD; Freiberg AN; Makino S
    Sci Rep; 2018 Nov; 8(1):17097. PubMed ID: 30459418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
    Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T
    Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].
    Wang QH; Wang XJ; Hu S; Ge JY; Bu ZG
    Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):677-81. PubMed ID: 17944371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
    Brahms A; Mudhasani R; Pinkham C; Kota K; Nasar F; Zamani R; Bavari S; Kehn-Hall K
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rift Valley Fever Phlebovirus Reassortment Study in Sheep.
    Balaraman V; Indran SV; Kim IJ; Trujillo JD; Meekins DA; Shivanna V; Zajac MD; Urbaniak K; Morozov I; Sunwoo SY; Faburay B; Osterrieder K; Gaudreault NN; Wilson WC; Richt JA
    Viruses; 2024 May; 16(6):. PubMed ID: 38932172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.
    Roberts KK; Hill TE; Davis MN; Holbrook MR; Freiberg AN
    J Gen Virol; 2015 Jul; 96(Pt 7):1651-1663. PubMed ID: 25759029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.